EISAI TO PRESENT NEW RESEARCH ON HALAVEN® (ERIBULIN) AT 37TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that new clinical study results on the company’s novel anticancer agent Halaven® (eribulin mesylate) will be presented during the 37th San Antonio Breast Cancer Symposium (SABCS). The symposium will be held from December 9 through 13, 2014, in San Antonio, Texas in the United States.

The studies reflect Eisai’s current and ongoing research efforts to establish the clinical benefits of Halaven and maximize the drug's value. The studies to be presented at this year’s SABCS highlight the company’s current oncology product portfolio strategy and research accomplishments in this field.

Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research in order to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.

The following Eisai abstracts are accepted for presentation at this year’s SABCS:

<table>
<thead>
<tr>
<th>Product</th>
<th>Abstract name and scheduled presentation date and time (local time)</th>
</tr>
</thead>
</table>
| Halaven (eribulin mesylate) | Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an open-label, phase II dose-confirmation study  
  Abstract no.: P3-13-04  
  Poster Session | December 11 (Thu), 17:00-19:00                                                                                                      |
| Halaven (eribulin mesylate) | Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis  
  Abstract no.: P3-13-06  
  Poster Session | December 11 (Thu), 17:00-19:00                                                                                                      |
| Halaven (eribulin mesylate) | Quality of life in patients receiving first-line eribulin mesylate for HER2- locally recurrent or MBC  
  Abstract no.: P5-17-02  
  Poster Session | December 12 (Fri), 17:00-19:00                                                                                                      |
| Halaven (eribulin mesylate) | Quality of life results from a phase II, multicenter, single-arm study of eribulin mesylate plus trastuzumab as first-line therapy for locally recurrent or metastatic HER2+ breast cancer  
  Abstract no.: P5-17-03  
  Poster Session | December 12 (Fri), 17:00-19:00                                                                                                      |
| Halaven (eribulin mesylate) | Eribulin mesylate plus capecitabine for adjuvant treatment in post-menopausal ER+ early-stage breast cancer: A phase II, multicenter, open-label study using 2 different dosage regimens  
  Abstract no.: P3-09-09  
  Poster Session | December 11 (Thu), 17:00-19:00                                                                                                      |

Media Inquiries:  
Public Relations Department,  
Eisai Co., Ltd.  
+81-(0)3-3817-5120